<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927365</url>
  </required_header>
  <id_info>
    <org_study_id>LC.001</org_study_id>
    <nct_id>NCT03927365</nct_id>
  </id_info>
  <brief_title>Muco-ciliary Cleansing of Lungs in COPD With and Without a Salt Particle Inhaler</brief_title>
  <official_title>Muco-ciliary Cleansing of Lungs in COPD With and Without a Salt Particle Inhaler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liita Care ApS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liita Care ApS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-over trial of the effect of a salt particle inhaler on pulmonary muco-ciliary cleansing
      in COPD patients as measured by lung scintigraphy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stable COPD patients will be examined twice with minimum two, maximum 14 days interval. In
      randomized order the patients will inhale from a salt particle inhaler with (active) or
      without (placebo) content.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants cross over from active to placebo or vice versa in random order</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization of a salt particle inhaler devices with (active) or without (placebo) content</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Muco-ciliary clearance</measure>
    <time_frame>Activity at time zero</time_frame>
    <description>Retention of inhaled radioactive marker in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muco-ciliary clearance</measure>
    <time_frame>Activity at time 30 minutes</time_frame>
    <description>Retention of inhaled radioactive marker in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muco-ciliary clearance</measure>
    <time_frame>Activity at time 90 minutes</time_frame>
    <description>Retention of inhaled radioactive marker in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muco-ciliary clearance</measure>
    <time_frame>Activity at time 120 minutes</time_frame>
    <description>Retention of inhaled radioactive marker in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Registering number of coughs</measure>
    <time_frame>Activity at any time between time zero and 120 minutes</time_frame>
    <description>Number of coughs during investigation is noted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of sputum</measure>
    <time_frame>Activity at any time between time zero and 120 minutes</time_frame>
    <description>Sputum during investigation is collected for analysis of radioactivity content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms in the subjects health</measure>
    <time_frame>Activity at time zero</time_frame>
    <description>Subjective symptom description during last 24 hours is done by a CCQ (Clinical COPD Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms in the subjects health</measure>
    <time_frame>Activity at time 30</time_frame>
    <description>Subjective symptom description during investigation is done by a questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms in the subjects health</measure>
    <time_frame>Activity at time 120</time_frame>
    <description>Subjective symptom description during investigation is done by a questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>COPD</condition>
  <condition>Copd Bronchitis</condition>
  <arm_group>
    <arm_group_label>Salt particle inhaler with content</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants inhaling from a salt particle inhaler with content</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salt particle inhaler without content</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants inhaling from a salt particle inhaler without content</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inhalation from a salt particle inhaler with or without content</intervention_name>
    <description>Inhalation from inhaler with (active) or without (placebo) content</description>
    <arm_group_label>Salt particle inhaler with content</arm_group_label>
    <arm_group_label>Salt particle inhaler without content</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD grade 1, 2 and 3 in stable condition (less than 10% change of FEV1 ratio between
             investigation visits

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients exposed to radionuclear isotopes within one month

          -  Patients under antibiotic treatment

          -  Patients with known hyper reactive airways
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jann Mortensen, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Clin Nuclear &amp; Physiolog dept.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jann Mortensen, MD Professor</last_name>
    <phone>+45 3545 4011</phone>
    <email>Jann.Mortensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zainab Saraj, Cand.Pharm</last_name>
    <phone>+45 22 26 88 65</phone>
    <email>zs@liitacare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet, Clin nuclear and physiolog dept.</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jann Mortensen, MD Professor</last_name>
      <phone>+45 3545 4011</phone>
      <email>Jann.Mortensen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

